Augmentin 250mg is a lower‑strength combination of amoxicillin and clavulanate, designed to provide broad antibacterial coverage with reduced clavulanate exposure. This dosage is commonly used in pediatric care (mg/kg‑based) and in adults with mild infections, offering effective beta‑lactam activity while minimizing gastrointestinal reactions associated with higher clavulanate loads. The formulation is available as standard tablets, capsules, and oral suspension, with the Suspension form frequently preferred for children due to flexible weight‑based dosing.
Clinical indications for Augmentin 250mg include acute otitis media, bacterial sinusitis, bronchitis, community‑acquired pneumonia, skin and soft‑tissue infections, and animal bites. Pediatric dosing guidance is detailed in the Pediatric section, while adult use typically applies to mild presentations where lower amoxicillin exposure is sufficient. Safety considerations—particularly GI tolerance—are outlined on the Side Effects and Interactions pages.
Compared with 500mg and 875mg strengths, Augmentin 250mg delivers a gentler clavulanate profile and is therefore better tolerated in sensitive patients. These comparisons help clarify clinical positioning and guide escalation when infection severity requires stronger dosing.
Augmentin 250mg is a lower‑strength formulation of the amoxicillin–clavulanate combination, designed to provide reliable beta‑lactam coverage with a reduced clavulanate load. This balance supports effective inhibition of bacterial cell‑wall synthesis while limiting gastrointestinal intolerance, making the 250mg strength a frequent choice in pediatric practice and in adults with mild to moderate infections. As a core member of the Augmentin family, it follows the same pharmacological principles outlined in the Augmentin overview, offering broad activity against common respiratory, ENT, and skin pathogens.
Clinically, Augmentin 250mg is used for acute otitis media, bacterial sinusitis, uncomplicated bronchitis, community‑acquired pneumonia, and various skin and soft‑tissue infections. Its lower amoxicillin content allows flexible mg/kg dosing in children, while adults may receive this strength when infection severity does not require escalation. The formulation is available across multiple oral forms, including tablets, capsules, and pediatric‑friendly suspension, supporting tailored administration based on age, weight, and swallowing ability.
Overall, Augmentin 250mg serves as a clinically versatile option within the amoxicillin–clavulanate class, offering dependable antimicrobial activity with improved tolerability. Its role is particularly strong in pediatric care and in early‑stage or mild infections where lower dosing is both sufficient and advantageous.
Augmentin 250mg is available in several oral formulations, allowing clinicians to match dosing convenience with patient‑specific needs. The most common option is the standard 250mg tablet, typically used in adults with mild infections or in adolescents who can swallow solid dosage forms. Tablets provide predictable absorption and are often chosen when fixed dosing is preferred; additional formulation details are outlined in the Tablets section.
Capsules containing 250mg of amoxicillin–clavulanate offer similar pharmacokinetics but may be easier for some patients to swallow. They are frequently used when tablet size or texture presents difficulties, and they maintain identical antimicrobial coverage. More information is available under Capsules.
The most flexible form is the oral suspension, commonly prepared as 250mg/5mL. This pediatric‑friendly formulation supports precise mg/kg dosing and is widely used in infants and younger children. Its ease of titration makes it ideal for variable weight‑ based regimens, with detailed guidance provided in the Suspension section. Together, these forms ensure Augmentin 250mg can be administered effectively across diverse age groups and clinical scenarios.
In adult patients, Augmentin 250mg is typically administered three times daily, a frequency that maintains adequate beta‑lactam exposure for mild respiratory, ENT, and skin infections. This regimen is commonly used when symptoms are early, uncomplicated, or when a lower clavulanate load is preferred to improve gastrointestinal tolerance. The 250mg strength offers a balanced option for mild presentations where escalation is not yet clinically necessary.
For moderate infections, clinicians often transition patients to stronger strengths such as 500mg, which provides higher amoxicillin exposure and more robust coverage against common pathogens. Severe or persistent infections may require further escalation to 875mg twice daily. These step‑up strategies help align antimicrobial intensity with infection severity while maintaining safety and tolerability.
| Strength | Frequency | Use |
|---|---|---|
| 250mg | 3×/day | Mild infections |
| 500mg | 2–3×/day | Moderate infections |
| 875mg | 2×/day | Severe infections |
Overall, adult dosing of Augmentin follows a severity‑based escalation model, ensuring that patients receive an appropriate balance of efficacy and tolerability across the available strengths.
Pediatric dosing of Augmentin relies on weight‑based calculations to ensure adequate antimicrobial exposure while minimizing unnecessary clavulanate intake. Standard regimens typically fall within 40–45 mg/kg/day of the amoxicillin component, divided into two or three doses depending on clinical presentation and formulation. This range is widely used for mild to moderate infections such as otitis media, sinusitis, and bronchitis, with structured guidance available in the Pediatric section.
In more severe cases—particularly refractory otitis media or pneumonia—dosing may be increased to 80–90 mg/kg/day. Dividing the total daily dose into multiple administrations helps maintain therapeutic beta‑lactam levels and supports consistent bacterial suppression. The suspension form, commonly prepared as 250mg/5mL, is especially useful for these calculations, allowing caregivers and clinicians to measure precise volumes based on weight and target mg/kg dosing.
| Weight (kg) | Daily Dose (mg) | Per Dose (mg) |
|---|---|---|
| 10 kg | 400–900 mg | 200–300 mg |
| 15 kg | 600–1350 mg | 300–450 mg |
| 20 kg | 800–1800 mg | 400–600 mg |
These structured mg/kg ranges ensure that Augmentin dosing remains both safe and effective across pediatric age groups, supporting individualized therapy based on weight, infection severity, and formulation choice.
Augmentin 250mg is commonly prescribed for mild to moderate community‑acquired infections where a lower amoxicillin–clavulanate load is sufficient. One of the most frequent uses is acute otitis media, particularly in pediatric patients who benefit from mg/kg dosing and the availability of suspension formulations. The 250mg strength also plays a central role in treating acute bacterial sinusitis, especially early or uncomplicated cases where escalation to higher doses is not yet required.
In respiratory infections, Augmentin 250mg is often used for uncomplicated bronchitis and mild community‑acquired pneumonia, providing reliable beta‑lactam coverage against common pathogens while maintaining good gastrointestinal tolerability. Its balanced profile makes it suitable for patients who may not tolerate higher clavulanate exposure.
Beyond respiratory and ENT indications, Augmentin 250mg is effective for mild skin infections and soft‑tissue involvement, including cellulitis and early abscesses. It is also frequently used for animal bites, where amoxicillin–clavulanate provides essential coverage against Pasteurella species and other mixed flora. Overall, the 250mg strength offers a versatile option for early‑stage or mild infections across both pediatric and adult populations.
Augmentin strengths are selected according to infection severity, patient tolerance, and clinical goals. The 250mg dose is typically used for mild infections, including early ENT and respiratory presentations, and is widely applied in pediatric care due to flexible mg/kg dosing. It provides adequate antimicrobial coverage with lower clavulanate exposure, improving GI tolerability.
For moderate infections, clinicians often transition to 500mg, which delivers higher amoxicillin levels and more robust pathogen suppression. This strength is a standard adult option for sinusitis, bronchitis, and pneumonia when symptoms are more pronounced or when initial low‑dose therapy is insufficient.
Severe infections or cases requiring maximal oral beta‑lactam exposure may necessitate escalation to 875mg. This high‑strength formulation is commonly used in advanced sinusitis, pneumonia, and complicated skin infections, offering stronger coverage while maintaining twice‑daily convenience.
| Strength | Best Use | Notes |
|---|---|---|
| 250mg | Mild infections | Pediatric/Adults |
| 500mg | Moderate infections | Standard adult dose |
| 875mg | Severe infections | High-strength |
This tiered structure helps clinicians match dosing intensity with clinical need, ensuring optimal efficacy while minimizing unnecessary clavulanate exposure.
Augmentin 250mg is generally well tolerated, but its safety profile is influenced by the clavulanate component, which is associated with gastrointestinal reactions such as nausea, abdominal discomfort, and diarrhea. Lower strengths like 250mg reduce clavulanate exposure, making them preferable for patients with sensitive GI systems or those who have previously experienced intolerance to higher doses. A detailed overview of common reactions is available on the Augmentin side effects page.
Allergic reactions remain an important consideration, particularly in individuals with a history of beta‑lactam or penicillin allergy. Symptoms may include rash, pruritus, or more severe hypersensitivity responses. Patients with known allergies should review guidance in the Penicillin allergy section before initiating therapy.
Dermatologic reactions such as mild rash can occur, especially in pediatric patients or during viral illnesses. While many rashes are benign, distinguishing between allergy‑related and non‑allergic skin reactions is essential for safe continued use. Overall, Augmentin 250mg maintains a favorable safety profile when used appropriately and with attention to individual risk factors.
Augmentin 250mg may interact with several commonly used medications, requiring careful monitoring and dose adjustments in specific clinical situations. One of the most notable interactions involves warfarin, where amoxicillin–clavulanate can potentiate anticoagulant effects by altering gut flora and vitamin K metabolism. Patients receiving warfarin should undergo closer INR monitoring during therapy, with additional guidance available in the Augmentin interactions section.
Allopurinol is another important interacting agent. When combined with Augmentin, the risk of dermatologic reactions—particularly rash—may increase. Although not universally observed, clinicians often exercise caution when co‑prescribing these medications, especially in patients with a history of drug‑related skin reactions.
Probenecid can significantly affect Augmentin pharmacokinetics by reducing renal excretion of amoxicillin, leading to elevated serum concentrations. This interaction may be used intentionally in certain therapeutic contexts but generally requires medical supervision to avoid excessive beta‑lactam exposure. Overall, awareness of these interactions helps ensure safe and effective use of Augmentin 250mg across diverse patient profiles.
Proper storage of Augmentin 250mg ensures stability, potency, and safe administration across all formulations. Tablets and capsules should be kept at standard room temperature, ideally in a dry environment away from direct sunlight and moisture. These solid forms maintain their integrity well under typical household conditions, making them straightforward to store for both short‑term and extended use.
The oral suspension requires more specific handling. Once reconstituted, Augmentin suspension must be stored in the refrigerator to preserve stability and prevent degradation of the active components. Most 250mg/5mL suspensions remain viable for 7–10 days, after which any remaining volume should be discarded. Detailed preparation and storage guidance is available in the Suspension section.
Ensuring correct storage conditions helps maintain therapeutic effectiveness and reduces the risk of dosing errors, particularly in pediatric settings where suspension use is common. Consistent adherence to these recommendations supports safe and reliable treatment outcomes.